Elicio Therapeutics is set to present new data on its lymph node-targeted, mKRAS-specific amphiphile vaccines at three upcoming conferences in September and October. These presentations will cover updates from the Phase I AMPLIFY-7P trial and insights into the clinical translation of Elicio's RAS-targeted vaccine platform.
AACR Special Conference on Pancreatic Cancer
Dr. Eileen O’Reilly from Memorial Sloan Kettering Cancer Center will present updates from the Phase I AMPLIFY-7P trial during a keynote lecture at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Pancreatic Cancer Research, held September 15-18, 2024, in Boston. The presentation, titled "Pancreas Cancer 2024: Translating genomic findings into clinical actionability," will take place on Sunday, September 15, at 5:50 p.m. ET.
RAS-Targeted Drug Development Summit
Elicio Therapeutics' Chief Scientific Officer, Dr. Pete DeMuth, will present at the RAS-Targeted Drug Development Summit on September 25, 2024, in Boston. His presentation, "Targeting mKRAS Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity," will focus on the clinical translation of Elicio’s RAS-targeted Amphiphile vaccines and is scheduled for Wednesday, September 25, at 11:45 a.m. ET.
Advances in Cancer Vaccines Summit
Dr. Christopher Haqq, Executive Vice President, Head of Research and Development and Chief Medical Officer of Elicio Therapeutics, will present Phase I experience with ELI-002 2P and ELI-002 7P at the Stuart and Molly Sloan Precision Oncology Institute Symposium: Advances in Cancer Vaccines Summit on October 1, 2024, in Seattle, Washington. The presentation, titled "Amplifying tumor specific immunity through lymph node targeted mKRAS-specific amphiphile vaccine in gastrointestinal tumors," is scheduled for Tuesday, October 1, at 9:40 a.m. PT.
According to Robert Connelly, Elicio’s Chief Executive Officer, recent data from patients who received the 7-peptide version of ELI-002 at the Phase 2 dose showed that T cell response data correlated with reductions in tumor biomarker levels and reduced risk of progression or death. The company anticipates providing additional clinical data updates from the AMPLIFY-201 trial in the fourth quarter of 2024 and the AMPLIFY-7P randomized Phase 2 interim analysis in the first quarter of 2025.
Elicio's AMP platform delivers immunotherapeutics directly to the lymph nodes by attaching to albumin in the bloodstream. Preclinical models have demonstrated that this lymph node-specific engagement drives therapeutic immune responses of increased magnitude, function, and durability.
